Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,861 matching trials from the live ClinicalTrials.gov search.
Filters: Chapel Hill, North Carolina Clear all
Recruiting No phase listed Observational

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

NCT02523118
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2051
U.S. locations
19
States / cities
Phoenix, Arizona • Rogers, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 30, 2026, 5:32 PM EDT
Recruiting Not applicable Interventional

Resilience Through Interventions for Successful Early Outcomes

NCT06669624
View directory record Official record
Conditions
Parenting Intervention, Stress, Caregiver Child Relationship, Child Behavior Problem, Mental Health
Interventions
Attachment and Biobehavioral Catch-up (ABC), Waitlist with 4-month delay, then ABC
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT02073279
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
20
States / cities
Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 30, 2026, 5:32 PM EDT
Completed No phase listed Observational

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

NCT01457768
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
158
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 30, 2026, 5:32 PM EDT
Terminated Phase 3 Interventional

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

NCT05964413
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
vilobelimab, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Hialeah, Florida • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody

NCT02069899
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Grand Rapids, Michigan • Chapel Hill, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

NCT01030432
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-650032, Placebo, Peginterferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Lower Limb Spasticity Follow-on Study

NCT01251367
View directory record Official record
Conditions
Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Scottsdale, Arizona • Downey, California • Oxnard, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 30, 2026, 5:32 PM EDT
Approved For Marketing No phase listed Expanded access

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

NCT06064500
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
U.S. locations
9
States / cities
New Haven, Connecticut • Miami Beach, Florida • Stuart, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Myocardial Ischemia and Transfusion

NCT02981407
View directory record Official record
Conditions
Myocardial Infarction, Anemia
Interventions
Red Blood Cell Transfusion
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
3,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
60
States / cities
Little Rock, Arkansas • Los Angeles, California • Danbury, Connecticut + 48 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Epic Allies HIV ART Adherence Intervention

NCT02782130
View directory record Official record
Conditions
HIV
Interventions
Epic Allies App Intervention, Epic Allies - Control Branch
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Tampa, Florida • Chicago, Illinois • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 30, 2026, 5:32 PM EDT
Recruiting No phase listed Observational

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

NCT06658730
View directory record Official record
Conditions
Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta, Aneurysm Thoracic, Aneurysm Dissecting, Transection Aorta, Intramural Hematoma
Interventions
Endovascular
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2038
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 5:32 PM EDT
Not listed Phase 1 Interventional

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

NCT00300807
View directory record Official record
Conditions
Hepatitis C
Interventions
XTL 6865
Drug
Lead sponsor
XTL Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Indianapolis, Indiana • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2007 · Synced Oct 30, 2026, 5:32 PM EDT
Withdrawn Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00054392
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
57
States / cities
Loma Linda, California • Pomona, California • New London, Connecticut + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

NCT03496571
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 30, 2026, 5:32 PM EDT
Completed No phase listed Observational Results available

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

NCT03888365
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil, Non-Treprostinil PAH Medications
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Timeline
2019
U.S. locations
10
States / cities
Birmingham, Alabama • Beverly Hills, California • Santa Barbara, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Evaluation of a Commercial Program on Weight Loss and Health Outcomes

NCT03037567
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Modified Weight Watchers plan
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Targeted Lifestyle Change Group Prenatal Care

NCT04090307
View directory record Official record
Conditions
Pregnancy, Gestational Diabetes
Interventions
TLC Group Prenatal Care
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years and older · Female only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 5:32 PM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 30, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

NCT02620046
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wheat Ridge, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 30, 2026, 5:32 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Prenatal Exposure Effects Psychophysiology Study

NCT01134770
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 30, 2026, 5:32 PM EDT
Recruiting No phase listed Observational

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT01351545
View directory record Official record
Conditions
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2041
U.S. locations
142
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 5:32 PM EDT
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
View directory record Official record
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 5:32 PM EDT